Report: Fosun Pharmaceuticals Considers Privatizing Hong Kong Stock Holding Subsidiary Fu Hong Han Lin
On Monday, according to media reports quoting people familiar with the matter, Fosun Pharmaceutical is considering a privatization acquisition of Fuhong Hanlin, which is listed on the Hong Kong stock market. People familiar with the matter said that Fosun Pharmaceuticals is cooperating with a consulting agency on a potential privatization offer plan, and other investors may also join the deal. Fuhong Hanlin is a holding subsidiary of Fosun Pharmaceutical. Fosun Pharmaceutical holds 53.61% of Fuhong Hanlin's total share capital. Since May 23, Fu Hong Hanlin has suspended trading on the Hong Kong Stock Exchange pending the announcement of the merger and acquisition. Negotiations are still ongoing, and it remains to be seen whether a deal will actually be reached in the future.
2024 Financial Report | Profit growth hit its lowest level in 10 years. Is Changchun Gaoxin's growth hormone ceiling here?
The time for the “first strain of growth hormone” to slow down has arrived. On March 20, Changchun Hi-Tech (000661.SZ) released its 2023 financial report, showing that current revenue and net profit to mother were 14.566 billion yuan and 4.532 billion yuan respectively, up 15.35% and 9.47% year-on-year respectively. This net profit growth rate to mother hit a record low since 2014. On March 20, Changchun Hi-Tech closed down 2.57%. Specifically, the current revenue and net revenue of Changchun Jinsai Pharmaceutical Co., Ltd. (hereinafter referred to as “Jinsai Pharmaceutical”), the core subsidiary responsible for growth hormone under Changchun Hi-Tech
Shanghai Fosun Pharmaceutical Reports 1H Results
Taizhou torrential rain A-share impact tracking: Jindick may have “no grain collection”, and the responses of more than 10 listed companies have no impact
The extreme weather during the typhoon season is having a potential impact on the production and operation activities of some listed companies. On July 17, the Taizhou Meteorological Observatory issued an orange warning signal for rainstorms, initiating a level-IV emergency response for flood control. Prior to that, beginning on July 6, rare heavy rain began to occur in the north-central region of the region. Whether this will adversely affect local companies is receiving market attention. According to Wind data, a total of 16 A-share companies have registered addresses in Taizhou. Some local companies have issued announcements confirming that production and operation have been impacted. On July 15, influenza vaccine company Kim Dick (688670.SH
Impacted by torrential rain: Kim Dick's revenue for the third quarter is likely to return to zero, and it has already fallen to a halt by 20cm intraday
A torrential rain in Taizhou, Jiangsu thundered Jin Dick (688670.SH), a company listed on the A-share Science and Technology Innovation Board. On July 14, Jindik issued an announcement stating that due to heavy rain in the Taizhou Pharmaceutical High-tech Zone (Gaogang District) where the company is located, the company's plant was flooded, and the production environment in some workshops was affected by water seepage. After continuous environmental monitoring and comprehensive assessment, the company decided to temporarily stop production of the influenza vaccine workshop on July 15. Kim Dick said that all of the company's revenue comes from the quadrivalent influenza vaccine. The production and sales of influenza vaccines have obvious seasonal characteristics. Every year, September-December is the peak season for influenza vaccine sales. Because of the flow
Zhaoyan's new drug to “hoard monkeys roll over” has come to a standstill
The fried monkey rolled over. Recently, the 2023 semi-annual report of Zhaoyan New Drug (603127.SH) predicted a sharp decline in net profit. According to the performance forecast, the net profit of Zhaoyan New Drug in the first half of 2023 is expected to be 73 million yuan to 110 million yuan, with a year-on-year decline range of 70.40% to 80.40%. Excluding the net profit of 188 million yuan in the first quarter of 2023, Zhaoyan New Pharmaceutical already lost money in the second quarter, only about -115 million yuan to -078 million yuan. However, at the same time, there was no sharp decline in revenue from Zhaoyan New Pharmaceuticals. In the first half of 2023